Mark Velleca, M.D., Ph.D.
Chief Executive Officer
Dr. Velleca joined G1 as Chief Executive Officer in 2014. Previously, he was at CGI Pharmaceuticals, where he guided the company from its inception through its establishment as a drug discovery company that brought multiple drug candidates into clinical trials. After Gilead Sciences acquired CGI, Dr. Velleca served as a senior advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Dr. Velleca was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.
Dr. Velleca earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University. He has served on the boards of directors and scientific advisory boards of several biotechnology companies, including Intellikine, an oncology therapeutics company acquired by Takeda in 2011. He most recently served as Executive Vice President at the Leukemia & Lymphoma Society.
Chief Commercial Officer
Mr. Demaree joined G1 as Chief Commercial Officer in 2018. In this role, he is responsible for all aspects of product commercialization, including marketing, sales, market access and commercial operations. Previously, Mr. Demaree served as Vice President, Oncology Marketing for Astellas where he led several product launches. He has worked for more than 20 years in oncology including roles of increasing leadership at Eli Lilly, Novartis and Abbott.
Mr. Demaree brings to G1 a strong history of building commercial capabilities and leading multiple successful new product and new indication launches. His areas of expertise include strategy, commercialization, new product launches, market access and reimbursement strategy, internal and external collaboration leadership, and business development and licensing.
Mr. Demaree received his B.S. in Marketing and his MBA in Marketing & Finance from Indiana University.
James Stillman Hanson
Mr. Hanson joined G1 as General Counsel in 2018, and leads the legal, compliance and quality functions at the company. Previously, Mr. Hanson served as Associate General Counsel and Vice President at IQVIA, where he led the Quintiles legal team in the merger of Quintiles and IMS Health to create QuintilesIMS (now IQVIA). In prior positions at Quintiles, Mr. Hanson negotiated strategic contracts, represented Quintiles in its initial public offering and was responsible for its public company securities reporting. Before joining Quintiles in 2010, he practiced corporate law, including merger and acquisitions, commercial contracting, securities reporting and corporate governance at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP, a Raleigh, North Carolina law firm.
Mr. Hanson is admitted to the North Carolina state bar. He earned his J.D. from the University of North Carolina School of Law and a B.A. in Economics and History from Wake Forest University.
Raj Malik, M.D.
Chief Medical Officer and Senior Vice President, R&D
Dr. Malik joined G1 in 2014. In his role as Chief Medical Officer and Senior Vice President, R&D, he leads the company’s clinical development, medical affairs, regulatory affairs, biometrics, translational medicine and preclinical teams. Previously, he served as Chief Medical Officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as Chief Medical Officer at Adherex Technologies, where he directed the company's global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb. Dr. Malik currently serves on the board of directors of Meryx, Inc.
Dr. Malik received his M.D. from the University of Sheffield Medical School in the UK. He completed his residency at Duke University Medical Center and fellowships at the Children's Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.
Chief Operating Officer
Mr. Murdock joined G1 in 2017. In his role as Chief Operating Officer, he is responsible for clinical operations, chemistry, manufacturing and controls (CMC), project management, product development outsourcing, IT, and facilities. Previously, Mr. Murdock served as Vice President and Global Head of the Oncology Center of Excellence at QuintilesIMS (now IQVIA), where he focused on developing insights and innovations that helped improve the probability of success for QuintilesIMS’ oncology customer development projects and programs.
Mr. Murdock has more than 20 years of work experience as a successful senior executive in the medical research industry, specializing in oncology, multiple sclerosis and other autoimmune diseases. Prior to QuintilesIMS, Mr. Murdock also held senior positions at Ergomed, Genzyme/Sanofi, ILEX Oncology and US Oncology.
Mr. Murdock earned his M.S. in biology and his B.S. in microbiology from the University of Texas, Arlington.
Barclay A. “Buck” Phillips
Chief Financial Officer and Senior Vice President, Corporate Development
Mr. Phillips joined G1 as Chief Financial Officer and Senior Vice President, Corporate Development in 2017. In this role, he has responsibility for the financial operations of the company including financial reporting, financial planning and analysis, financing strategy and treasury. In addition, Mr. Phillips is responsible for investor relations, business development and strategic transactions. Previously, he served as Chief Financial Officer of two publicly traded biotech companies: Novavax, Inc., and Micromet, Inc., an oncology company acquired by Amgen in 2012. He started his career in various role of increasing responsibility in the healthcare investment industry with Vector Fund Management and INVESCO Funds Group.
Mr. Phillips brings almost 30 years of biotech-specific finance and business experience to G1, providing the company with a unique blend of biotech executive, investor and board member experience. Mr. Phillips received a B.A. in economics from the University of Colorado, Boulder.
Jay Strum, Ph.D.
Chief Scientific Officer
Dr. Strum joined G1 as its first employee and founding Chief Scientific Officer in 2009. He is responsible for directing the company's discovery efforts and is a co-inventor on more than 60 issued patents assigned to G1. Dr. Strum was instrumental in building G1’s kinase drug discovery platform and in recruiting, leading and managing the preclinical research team. Prior to G1, Dr. Strum led drug discovery programs in cancer and metabolic diseases at GlaxoSmithKline, where he brought multiple drug candidates into clinical development.
Dr. Strum obtained his Ph.D. in biochemistry from Wake Forest University and did postdoctoral work with Dr. Bob Bell in molecular cancer biology at Duke University. His broad multidisciplinary experience in research and development includes being an author on more than 40 scientific papers and three book chapters.